Overview

  • Product name

    Human Lipoprotein A ELISA Kit
    See all Lipoprotein a kits
  • Detection method

    Colorimetric
  • Precision

    Intra-assay
    Sample n Mean SD CV%
    Serum 5 1.8%
    Inter-assay
    Sample n Mean SD CV%
    Serum 3 2%
  • Sample type

    Urine, Serum, Heparin Plasma, EDTA Plasma, Citrate Plasma, Cerebral Spinal Fluid
  • Assay type

    Sandwich (quantitative)
  • Sensitivity

    2.5 ng/ml
  • Range

    17.2 ng/ml - 1100 ng/ml
  • Recovery

    Sample specific recovery
    Sample type Average % Range
    Cell culture supernatant 102 99% - 105%
    Urine 107 107% - 108%
    Serum 99 97% - 103%
    Heparin Plasma 104 100% - 107%
    EDTA Plasma 104 101% - 108%
    Citrate Plasma 102 99% - 105%
    Cerebral Spinal Fluid 109 108% - 110%

  • Assay time

    1h 30m
  • Assay duration

    One step assay
  • Species reactivity

    Reacts with: Human
    Does not react with: Mouse, Rat, Cow
  • Product overview

    Lipoprotein A in vitro SimpleStep ELISA® (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of human Lipoprotein A protein in human serum, plasma, urine, and cerebrospinal fluid.


    The SimpleStep ELISA® employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material.  TMB substrate is added and during incubation is catalyzed by HRP, generating blue coloration. This reaction is then stopped by addition of Stop Solution completing any color change from blue to yellow. Signal is generated proportionally to the amount of bound analyte and the intensity is measured at 450 nm. Optionally, instead of the endpoint reading, development of TMB can be recorded kinetically at 600 nm.

  • Notes

    Lipoprotein A is an atherogenic lipoprotein particle formed by an assembly of LDL particles and apo(a) bound to apoB-100 component of LDL. Apolipoprotein A, the main constituent of Lipoprotein A, has serine proteinase activity and is capable of autoproteolysis. Apolipoprotein A has 4,548 amino acids, variable sizes from 200 to 700 kDa, multiple isoforms, and structural homology with plasminogen. It competes with plasminogen for its binding site, inhibiting tissue-type plasminogen activator 1 and leading to reduced fibrinolysis. High levels of Lipoprotein A in the blood is a risk factor for myocardial infarction (MI), coronary heart disease (CHD), cerebrovascular disease (CVD), atherosclerosis, thrombosis, and stroke.

  • Tested applications

    Suitable for: Sandwich ELISAmore details
  • Platform

    Pre-coated microplate (12 x 8 well strips)

Properties

  • Storage instructions

    Store at +4°C. Please refer to protocols.
  • Components 1 x 96 tests
    10X Human Lipoprotein A Capture Antibody 1 x 600µl
    10X Human Lipoprotein A Detector Antibody 1 x 600µl
    10X Wash Buffer PT (ab206977) 1 x 20ml
    Antibody Diluent CPI 1 x 6ml
    Human Lipoprotein A Lyophilized Recombinant Protein 2 vials
    Plate Seals 1 unit
    Sample Diluent NS 1 x 50ml
    SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit
    Stop Solution 1 x 12ml
    TMB Development Solution 1 x 12ml
  • Research areas

  • Relevance

    Lipoprotein(a) (Lp(a)) is a lipoprotein subclass assembled in the blood from low density lipoprotein (LDL) molecules and apolipoprotein-a (apo-a). Lp(a) recruits inflammatory cells through interaction with Mac-1 integrin. High Lp(a) in blood is a risk factor for coronary heart disease, cerebrovascular disease, atherosclerosis, thrombosis, and stroke. Lp(a) concentrations may be affected by disease states, but are only moderately affected by diet, exercise and other environmental factors. Lipid-reducing drugs have no effect on Lp(a) concentration. High Lp(a) predicts risk of early atherosclerosis similar to high LDL, but in advanced atherosclerosis, Lp(a) is a risk factor independent of LDL, indicating a coagulant risk of plaque thrombosis. Apo(a) contains domains that are very similar to plasminogen (PLG). Lp(a) accumulates in the vessel wall and inhibits binding of PLG to the cell surface, reducing plasmin generation which increases clotting. This inhibition also promotes proliferation of smooth muscle cells. These unique features of Lp(a) suggest a role in the generation of clots and atherosclerosis.
  • Alternative names

    • AK38
    • Antiangiogenic AK38 protein
    • apo(a)
    • APOA
    • apolipoprotein(a)
    • LP
    • lp(a)
    • LPA
    see all
  • Database links

Applications

Our Abpromise guarantee covers the use of ab212165 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA Use at an assay dependent concentration.

Images

  • SimpleStep ELISA technology allows the formation of the antibody-antigen complex in one single step, reducing assay time to 90 minutes. Add samples or standards and antibody mix to wells all at once, incubate, wash, and add your final substrate. See protocol for a detailed step-by-step guide.

     

  • Background-subtracted data values (mean +/- SD) are graphed.

  • The concentrations of Lipoprotein A were measured in duplicate, interpolated from the Lipoprotein A standard curve, and corrected for sample dilution. Undiluted samples are as follows: serum 0.25%, plasma (citrate) 0.25%, plasma (heparin) 0.25% and plasma (EDTA) 0.125%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean Lipoprotein A concentration was determined to be 309 μg/mL in serum, 291 μg/mL in plasma (citrate), 520 μg/mL in plasma (EDTA), and 150 μg/mL in plasma (Heparin).

  • The concentrations of Lipoprotein A were measured in duplicates, interpolated from the Lipoprotein A standard curves and corrected for sample dilution. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean Lipoprotein A concentration was determined to be 500 ng/mL in urine, and 130 ng/mL in cerebrospinal fluid.

  • Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean Lipoprotein A concentration was determined to be 169 µg/mL with a range of 42 – 576 µg/mL.

Protocols

References

ab212165 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab212165.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up